(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of 6.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Maravai Lifesciences Holdings's revenue in 2026 is $192,283,000.On average, 13 Wall Street analysts forecast MRVI's revenue for 2026 to be $53,059,167,433, with the lowest MRVI revenue forecast at $48,077,998,365, and the highest MRVI revenue forecast at $58,746,087,354. On average, 9 Wall Street analysts forecast MRVI's revenue for 2027 to be $57,145,362,592, with the lowest MRVI revenue forecast at $51,016,069,853, and the highest MRVI revenue forecast at $63,499,677,342.
In 2028, MRVI is forecast to generate $59,658,960,741 in revenue, with the lowest revenue forecast at $55,506,281,805 and the highest revenue forecast at $65,059,489,011.